Revolution Medicines saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 67 to 74.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 in the early stages of their moves. See if Revolution Medicines can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
While the stock is not near a proper buy zone right now, see if it goes on to form and break out of a proper base.
Revolution Medicines reported 0% EPS growth in its most recent report. Sales increased -100%.
Revolution Medicines earns the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
